Summary:
In-vivo CAR-T therapy delivers genetic instructions to immune cells inside the patient, aiming to reduce ex-vivo manufacturing constraints, shorten time to treatment, and scale cell therapy as a single-dose or redosable approach.
A recent Pharma Focus Europe article featuring Novotech highlights viral and non-viral delivery platforms, early clinical learnings across oncology and autoimmune disease, and the safety, CMC, and global regulatory strategies needed for precise cell targeting, durable CAR expression, and controllable activity.